title: [Effects of Jinlong Capsule on expressions of interleukin-2 and soluble interleukin-2 receptor in patients with primary liver cancer after transarterial chemoembolization therapy].
abstract: OBJECTIVE
  To observe and discuss the dynamic changes of interleukin-2 (IL-2) and soluble interleukin-2 receptor (sIL-2R) and their significance in the patients with primary liver cancer after transarterial chemoembolization (TACE) therapy combined with Jinglong Capsule.
  
  
  METHODS
  A total of 48 patients with primary liver cancer, who failed to be treated by major surgery, were randomly divided into two groups: Jinlong Capsule group (TACE therapy plus Jinlong Capsule) and control group (TACE therapy alone). There were 24 cases in each group. The levels of peripheral blood IL-2 and slL-2R were measured before the first TACE and 1, 7 and 15 days after the second TACE respectively by using double-antibody sandwich enzyme-linked immunosorbent assay. The data from Jinlong Capsule group were compared with those from the control group.
  
  
  RESULTS
  The level of sIL-2R in Jinlong Capsule group was significantly lower than that in the control group (P<0.05), while the level of IL-2 was significantly higher than that in the control group (P<0.05).
  
  
  CONCLUSIONS
  Jinlong Capsule can significantly improve the lymphocyte function of the patients with primary liver cancer after TACE. The levels of IL-2 and sIL-2R can be considered as the valuable parameters for evaluating the effects on primary liver cancer, and Jinlong Capsule is helpful for the patients with primary liver cancer.
authors.affiliation: Department of Radiology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
authors.forename: Huo-Jun
authors.initials: HJ
authors.lastname: Zhang
authors.forename: Ji-Jin
authors.initials: JJ
authors.lastname: Yang
authors.forename: Wei-Xing
authors.initials: WX
authors.lastname: Wang
authors.forename: Xu
authors.initials: X
authors.lastname: Jiang
authors.forename: Yan-Jun
authors.initials: YJ
authors.lastname: Mao
authors.forename: Chao-Ai
authors.initials: CA
authors.lastname: Yang
authors.forename: Ji-Xiang
authors.initials: JX
authors.lastname: Guo
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002214:Capsules; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000188:drug therapy; D016461:Chemoembolization, Therapeutic / Q000379:methods; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000097:blood*; D008113:Liver Neoplasms / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D015375:Receptors, Interleukin-2 / Q000097:blood*
chemical_list: D000276:Adjuvants, Immunologic; D002214:Capsules; D004365:Drugs, Chinese Herbal; C508594:IL2 protein, human; D007376:Interleukin-2; D015375:Receptors, Interleukin-2